Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer’s disease

Antibody therapies for Alzheimer’s Disease (AD) hold promise but have been limited by the inability of these proteins to migrate efficiently across the blood brain barrier (BBB). Central nervous system (CNS) gene transfer by vectors like adeno-associated virus (AAV) overcome this barrier by allowing...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmer, Bradford M., Swanson, Kurt A., Bangari, Dinesh S., Piepenhagen, Peter A., Roberts, Errin, Taksir, Tatyana, Guo, Lei, Obinu, Maria-Carmen, Barneoud, Pascal, Ryan, Susan, Zhang, Bailin, Pradier, Laurent, Yang, Zhi-Yong, Nabel, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936806/
https://www.ncbi.nlm.nih.gov/pubmed/31887144
http://dx.doi.org/10.1371/journal.pone.0226245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936806/
https://www.ncbi.nlm.nih.gov/pubmed/31887144
http://dx.doi.org/10.1371/journal.pone.0226245

Ejemplares similares